Filing Flows › Comparisons › BMY vs GSK
Bristol Myers Squibb vs GSK: BMY and GSK compared
Bristol Myers Squibb is the larger company: $13.1B of revenue in its latest quarter (Q3 2026) against $8.5B for GSK (Q3 2026). GSK is more profitable, with an operating margin of 30.3% against 19.4%.
Where the money goes: BMY and GSK
Bristol Myers Squibb (BMY) · Q3 2026
Bristol Myers Squibb, Q3 2026: revenue $13.1B (+7% year over year), operating margin 19.4%, net earnings $2.2B, operating cash flow $4.2B. The chart follows the revenue to costs, profit and cash.
GSK (GSK) · Q3 2026
GSK, Q3 2026: revenue $8.5B, operating margin 30.3%, net earnings $2.0B. The chart follows the revenue to costs, profit and cash.
| Bristol Myers Squibb (BMY) | GSK (GSK) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $13.1B | $8.5B |
| Revenue growth, Y/Y | +7% | — |
| Gross margin | — | 73.6% |
| Operating margin | 19.4% | 30.3% |
| Net earnings | $2.2B | $2.0B |
| Net margin | 16.5% | 23.6% |
| Operating cash flow | $4.2B | — |
| Free cash flow | $3.8B | — |
| Market value | $127.6B | — |
| P/E | 13.7× | — |
| Analysts’ mean target | $65.25 | — |
Where the revenue comes from
Bristol Myers Squibb
- Net product sales: $12.6B (97%)
- Camzyos: $420M (3%)
GSK
- Specialty Medicines: $3.9B (45%)
- Dolutegravir products: $1.4B (17%)
- Dovato: $754M (9%)
- Long Acting Injectables: $621M (7%)
Questions
Which is bigger, Bristol Myers Squibb or GSK?
Bristol Myers Squibb is the larger company: $13.1B of revenue in its latest quarter (Q3 2026) against $8.5B for GSK (Q3 2026).
Is Bristol Myers Squibb or GSK growing faster?
GSK is more profitable, with an operating margin of 30.3% against 19.4%.
More: Bristol Myers Squibb earnings · how Bristol Myers Squibb makes money · GSK earnings · how GSK makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 29, 2026; 6-K filed Oct 28, 2026). Fiscal quarters can end on different dates. Not investment advice.